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Jaime M. Preussler,1 Ellen M. Denzen,1 Navneet S. Majhail1,2Interest is growing in economic and comparative effectiveness analyses, with increasing emphasis on optimiz-
ing healthcare resources and costs. Limited information is available on the economic aspects of hematopoi-
etic cell transplantation (HCT). We review contemporary literature on the costs and cost-effectiveness of
HCT in the United States and worldwide. Published studies confirm the high costs associated with HCT, al-
though the reported costs are highly variable, related to the differing methodologies used across studies.We
examine the challenges in reviewing costs and cost-effectiveness across studies specific to HCTand highlight
factors identified as associated with higher costs of HCT.We also discuss opportunities for future research in
this area.
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Hematopoietic cell transplantation (HCT) is the
preferred therapy for many patients with high-risk he-
matopoietic disease. Annually, approximately 55,000
HCTs are performed worldwide, including 20,000 in
the United States [1]. This number is expected to in-
crease with continuing improvements in transplanta-
tion technology and supportive care practices and the
emergence of new indications and alternative graft
sources [2,3].
HCT is a highly specialized, resource-intense, and
costly medical procedure, A 2009 Agency for Health-
care Research and Quality report using data from the
Healthcare Cost andUtilization Project noted that de-
spite being a relatively uncommon procedure, HCT
was among the top 10 procedures with the greatest in-
crease in hospital costs. Between 2004 and 2007,
HCT-associated hospital costs increased by 85%,
from $694 million to $1.3 billion, related to increases
in both costs and the number of hospitalizations [4].
HCT-associated costs will become an increasingly im-1Health Services Research Program, National Marrow
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tion of this treatment. In this article, we review the
available literature on the costs and cost-effectiveness
of HCT to summarize what is known about these
costs, identify the drivers of these costs, highlight lim-
itations of the literature, and describe opportunities for
further research in this area.ECONOMIC ANALYSIS IN HEALTHCARE:
A PRIMER FOR TRANSPLANTATION
PROVIDERS
In a society with finite health care resources, it is
important to understand the costs and benefits of med-
ical interventions to evaluate whether they provide
good value [5,6]. There are various ways to analyze
costs, including cost identification, cost-effectiveness,
cost-utility, and cost-benefit analyses (Table 1). The
method used depends on the purpose of the research
and the data available [7-16].
Various issues must be considered when reviewing
economic studies of HCT. Waters et al. [13] reviewed
and provided a structure for reviewing cost and cost-
effectiveness studies related to HCT.Types of Direct Medical Costs Evaluated
Direct costs consist of the value of goods, services,
and resources consumed in the delivery of a medical
treatment and can include costs of drugs, supplies, ra-
diologic investigations, laboratory services, and health
care personnel [17]. Studies of HCT costs differ in the
types of direct costs they include. Examples of direct
cost categories that have been variably included are
Table 1. Methods of Analyzing Healthcare Costs
Method Characteristics
Cost identification or cost-minimization analysis  Compares costs of 2 or more interventions with the assumption that their outcomes are similar
Cost-effectiveness analysis  Compares net costs of 2 or more interventions in monetary units with their effectiveness (e.g., survival)
 ICER is calculated (ratio of difference in costs versus difference in effectiveness)
 Less costly andmore effective intervention preferred over more costly and less or equally effective therapy
Cost-utility analysis  A type of cost-effectiveness analysis that incorporates quality-of-life considerations in the outcomes
 Results are expressed as cost per quality-adjusted life-year gained
 Survival time is adjusted using ‘‘patient utilities’’ (ranging from 0 for death to 1 for full health)
Cost-benefit analysis  Assigns a dollar value to clinical benefit and estimates net financial impact of an intervention
 Not commonly performed in medicine, given the challenges in assigning monetary value to health or
a disease state
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lated to donor search and graft procurement, costs of
outpatient prescription drugs and home care services,
and costs of physician services.
Inclusion of Direct Nonmedical and Indirect
Costs
These costs generally include patient-related di-
rect nonmedical costs (eg, out-of-pocket costs, ex-
penses related to transportation and lodging) and
indirect costs related to the loss of patient and care-
giver productivity (ie, current and future wages)
[17,18]. These costs can be difficult to capture and
are defined inconsistently across studies [17].
Perspective of Economic Analysis
The specific question addressed by an economic
analysis can determine which costs are included. For
example, inclusion of indirect costs is relevant for anal-
yses performed from a societal or patient perspective,
but might not be as important when studying the eco-
nomic impact of an intervention from a payor’s or hos-
pital’s perspective.
Time Frame
There can be substantial variation in the time
horizons considered both before and after transplanta-
tion. This can lead to differences in the costs reported
for the same procedure. For instance, unlike studies
that follow patients through only day-100 posttrans-
plantation, studies that follow patients for a longer
period can include costs related to chronic graft-
versus-host disease (GVHD).
Patient Mix and Practice Patterns
The availability of local resources, characteristics
of patients undergoing HCT, and the practice styles
of individual transplantation centers and medical pro-
viders can have an impact on transplantation costs.
The majority of economic analyses in HCT are
single-center studies, and the reported costs reflect
that center’s patient mix, practice patterns, and trans-
plantation protocols.Methods of Estimating and Metrics Used to
Describe Costs
Studies vary in the methods used to obtain cost
information, and a variety of metrics may be used to
describe costs of HCT. Examples of methods of ob-
taining costs include using information from data-
bases, the hospital accounting system, and review of
patient medical records.
International Differences
Reimbursement mechanisms vary by country.
Some countries have a single governmental payor,
whereas others, including the United States, have mul-
tiple payors, which can include a mix of governmental
and private payors.METHODS
We searched the literature for English language
articles on HCT costs and cost-effectiveness using
the MEDLINE (PubMed) database. We limited our
search to articles published between January 2000
and July 2011 to obtain a more contemporary perspec-
tive of costs for this procedure. The search terms for
costs included ‘‘comparative effective,’’ ‘‘economic
analysis,’’ ‘‘economic evaluation,’’ ‘‘cost-minimiza-
tion,’’ ‘‘cost-effective,’’ ‘‘cost,’’ ‘‘cost-benefit,’’ and
‘‘cost-utility.’’ The search terms for HCT included
‘‘allogeneic bone marrow transplant,’’ ‘‘autologous
bone marrow transplant,’’ ‘‘unrelated bone marrow
transplant,’’ ‘‘hematopoietic stem cell transplant,’’ ‘‘he-
matopoietic cell transplant,’’ ‘‘peripheral blood stem
cell transplant,’’ ‘‘stem cell transplant,’’ ‘‘PBSCT,’’
‘‘HSCT,’’ ‘‘HCT,’’ and ‘‘cord blood transplant.’’ Bibli-
ographies of source articles were hand-searched for ad-
ditional relevant references. Studies that described
economic evaluation of HCT and included patients di-
agnosed with cancer or other diseases commonly treat-
able by HCT (excluding breast cancer) were included
in our review. A total of 205 abstracts were identified.
Screening of titles and abstracts identified 30 articles
that provided information on costs and cost-
effectiveness. On further review, 10 of these articles
1622 Biol Blood Marrow Transplant 18:1620-1628, 2012J. M. Preussler et al.were excluded because they were narrative reviews, did
not describe costs, consisted of more than one publica-
tion using the same data, or described rare indications
for HCT (ie, multiple sclerosis and thalassemia). The
20 original articles that provided information on
HCT costs and cost-effectiveness are described. De-
tailed descriptions of these 20 articles are available in
an online supplement.HCT COST IDENTIFICATION STUDIES
Costs of HCT
Cost identification studies from the United States
(US) and from international centers are summarized
in Tables 2 and 3. Almost all of the US studies are
single-institution studies (Table 2). The majority un-
derestimate the total costs of HCT, because they do
not include data on costs outside of the transplant cen-
ter (eg, outpatient medications, home infusions), do-
nor search and graft procurement, and physician
charges. Furthermore, because of the differences in
types of costs included and time horizons considered,
the costs of HCT in the US vary considerably, and
a generalizable nationally representative estimate of
the costs of allogeneic or autologous HCT cannot be
derived.
Among recipients of allogeneicHCT, costs vary by
donor source and conditioning regimen intensity,
ranging from $80,499 to $137,564 in more contempo-
rary studies. Majhail et al. [19] reported median costs
of $83,583 for related donor HCT and $137,564 for
umbilical cord blood (UCB) HCT through 100 days
posttransplantation. They also reported a median
cost of $137,112 for myeloablative conditioning
HCT and $84,824 for reduced-intensity conditioning
(RIC) HCT [19]. Saito et al. [20] found a similar pat-
tern when examining costs over 1 year posttransplanta-
tion, reporting median 1-year costs of $128,253 for
myeloablative HCT and $80,499 for RIC HCT. In
a later study evaluating allogeneic HCT with related
and unrelated donors, Saito et al. [21] found higher
costs associated with unrelated donor HCT compared
with related donor HCT.
Autologous HCT is generally less costly than allo-
geneic HCT. Lee et al. [22] reported a mean cost of au-
tologous transplantation fromadmission until discharge
of $55,500, just slightlymore than half that of allogeneic
HCT ($105,300). Using data from the Nationwide
Inpatient Sample, Jones et al. [23] found a mean cost
of $51,312 for hospitalization for autologous HCT.
International cost studies are described in Table 3.
More of the international studies included multiple in-
stitutions compared with the US studies, although the
international studies generally included a smaller
number of patients. Some studies had findings similar
to those reported in the US studies; for example, ina single-institution study from Sweden, Svahn et al.
[24] found lower costs for HCT with related donor
transplantations compared with HCT with unrelated
donor transplantations (V129,133 versus V160,658).
Some international studies reported contrasting find-
ings to the US studies. Examining costs over a 12-
month period in France, Cordonnier et al. [25] found
that myeloablative transplantations cost less than
RIC transplants (V74,900 versus V78,700), although
the difference was not statistically significant. In a sin-
gle-institution study in Thailand, Ngamkiatphaisan
et al. [26] found lower costs for allogeneic HCT com-
pared with autologous HCT over 1-year posttrans-
plantation. Economic evaluations of HCT are
difficult to compare between countries because of dif-
ferences in health care systems, transplantation cover-
age, and payment policies.
Factors Associated with High Costs
Even given the differences in US and international
studies, similar factors were found to be associated
with increased costs across studies. The most common
drivers of total costs were costs related to hospitaliza-
tion, treatment of complications, and transplantation
for more advanced disease.
Costs related to hospitalization generally were the
major cost contributors across the studies, and costs
associated with the initial hospitalization for HCT
were identified as the main driver of total costs in the
first 100 days posttransplantation [21,22]. In general,
costs of HCT within the first 100 days were
closely associated with the length of hospital stay.
Although many types of costs are incurred during
hospitalization, medical staff costs, room and board,
pharmacy, laboratory services, radiology, blood bank,
and blood products were identified as the major cost
contributors [19,21,22,27,28].
Posttransplantation complications are a major
contributor to HCT costs and tend to be associated
with the duration of hospitalization as well. Saito
et al. [21] found that costs rise by an average of
$20,228 per complication. Jones et al. [23] reported
that hospitalizations without complications were the
least expensive and cost less than the average HCT
regardless of the patient’s diagnosis. Studies have sug-
gested that decreasing the risk of severe complications
could reduce overall costs.
Disease status also plays a role in driving up the
cost of HCT. Saito et al. [21] reported higher costs
in patients with advanced disease compared with those
with less advanced disease. Most of the articles also
noted that costs were a reflection of the patient mix
in the individual transplantation centers.
The majority of cost-identification studies to date
have focused on early costs of HCT. The economic
impacts of long-term care and chronic GVHD are
not clear.
Table 2. Summary of Cost-Identification Studies of HCT in the United States Published after 2000
Reference Data Source Population Characteristics Costs Conclusions/Remarks
Lee et al. [22] Single institution, 1994-1997
Time horizon: hospital admission for
conditioning until discharge
n 5 236 (auto, allo: MRD, URD)
Inpatient only; adult patients
Median costs:
Auto: $55,500
Allo: $105,300
Overall costs were significantly higher for allo-HCT than for auto-HCT.
Higher costs were driven by occurrence of major complications.
Use of mismatched donors among allo-HCT recipients was a significant
pre-HCT predictor of costs.
Saito et al. [20] Single institution, 2000-2003
Time horizon: graft infusion through 1 year
post-HCT
n 5 275 (allo: MA, RIC)
Inpatient and outpatient; adult patients
Median costs:
Allo-MA: $128,253
Allo-RIC: $80,499
For 1 year after allo-HCT, RIC HCTwas less expensive than MA HCT
with comparable clinical outcomes.
Costs were significantly higher for unrelated donor HCT than for related
donor HCT.
HCTwas more costly for patients with advanced disease than for those
with less advanced disease.
Saito et al. [21] Single institution, 2000-2004
Time horizon: admission to 1 year post-HCT
n 5 315 (allo: MRD, MUD)
Inpatient only; adult patients
Median total cost over first
year: $128,800
Room, pharmacy, and blood bank costs were the largest contributors to
total costs in first 100 days post-HCT.
Pretransplantation predictors of higher costs included the use of
unrelated donors and advanced disease status.
Both before and after HCT, complications were associated with higher
costs.
Majhail et al. [19] Single institution, 2004-2006
Time horizon: from 30 days before until 100
days after HCT
n 5 294 (MA: MRD, UCB; RIC: MRD, UCB)
Inpatient and outpatient; adult patients
Median costs:
MA: $137,112
RIC: $84,824
UCB: $137,564
MRD: $83,583
Room and board and pharmacy services were the major contributors to
total costs.
UCB HCTwas more expensive than MRD HCT, and MA HCTwas more
expensive than RIC HCT.
Costs for both UCBHCTandMRDHCTwere driven primarily by severe
posttransplantation complications and prolonged inpatient stay.
Majhail et al. [28] Single institution, 2004-2006
Time horizon: from 30 days before until 100
days after HCT
n 5 146 (allo: MRD, MUD, UCB)
Inpatient and outpatient; pediatric patients
Mean cost per day survived:
MRD: $3,446
MUD: $4,050
UCB: $4,522
Costs of MUD HCTand UCB HCTwere similar; MRD HCTwas less
costly.
Room and board and pharmacy services were major contributors to
total costs.
Costs were driven primarily by post-HCT complications.
Jones et al. [23] Secondary database analysis (HCUP NIS),
2000-2001
Time horizon: admission to discharge for
single HCT hospitalization
n 5 8,891 (auto)
Inpatient only; adult patients
Mean costs: $51,312 Complications were associated with increased hospital costs.
Use of total body irradiation was associated with longer hospital stay and
higher hospital costs.
Allo indicates allogeneic; auto, autologous; HCUP NIS, Healthcare Cost and Utilization Project Nationwide Inpatient Sample; MA, myeloablative; MRD, matched related donor; MUD, matched unrelated donor.
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Table 3. Summary of Cost Identification Studies of HCT from Countries Other Than the United States Published after 2000
Reference Data Source Population Characteristics Costs Conclusions/Remarks
Ngamkiatphaisan et al. [26] Thailand; single institution;
1994-2005
Time horizon: 1 year post-HCT
n 5 67 (allo: PBSC, BM; auto: PBSC)
Inpatient and outpatient; pediatric and adult patients
Total costs of HCT:
Auto: V24,171
Allo: V22,593
Drug costs were the major cost driver for allo-HCT.
Routine service costs (labor, material, capital costs, and
indirect costs) were cost drivers of auto-HCT.
Svahn et al. [24] Sweden; single institution; 1998-1999
Time horizon: day of admission through
5 years after HCT
n 5 93 (allo: MRD, MUD, mismatched UD)
Inpatient and outpatient; pediatric and adult patients
Median total costs:
MRD: $129,133
MUD: V160,658
Total costs were higher in patients with acute leukemia
than in those with all other diagnoses.
Costs were highest during the first year post-HCT.
Total costs were similar for MUD HCTand MRD HCT
over the 5-year period; cost drivers included
hospitalization and complications.
Mishra et al. [31] Norway; single institution; 1999-2000
Time horizon: pre-HCT phase through
1 year post-HCT
n 5 17 (allo: MRD, MUC, PBSC, BM)
Inpatient only; adult patients
Median total costs: $69,270 In the transplantation phase, mean personnel costs
represented 54% of the total costs.
A correlation was found between length of stay and
hospital cost.
Esperou et al. [32] France; 19 centers; 1998-2000
Time horizon: through 24 months post-HCT
n 5 85 (allo: MRD PBSC, BM)
Inpatient and outpatient; pediatric and adult patients
Mean total costs: V76,237 The major cost driver was total hospital days.
Among complications, predictors of costs were GVHD
and more than 2 documented infections (added costs
of $20,000-$30,000).
Cordonnier et al. [25] France; 2 centers; 1998-2003
Time horizon: first day of hospitalization
before conditioning regimen, through
12 months post-HCTor death
n 5 23 (allo-MRD: MA, RIC)
Inpatient and outpatient; adult patients
Mean total costs:
MRD-MA: V74,900
MRD-RIC: $78,700
The major cost driver was length of stay.
Mean 1-year total costs did not differ significantly
between the 2 groups.
Total costs not different during the first 6 months but
were significantly higher in the RIC group during the
last 6 months.
Faucher et al. [33] France; 3 centers; 2001-2005
Randomized trial of early discharge versus
standard hospital-based follow-up
Time horizon: day of PBSC harvest until
day-60 post-HCT
n 5 131 (auto-PBSC HCT: early discharge; standard
inpatient)
Inpatient and outpatient; adult patients
Mean total cost:
Early discharge: $9,777
Standard inpatient: V10,436
Majore cost drivers for both arms were hospitalization
and medications.
Early discharge led to 20% decrease in post-auto-HCT
hospitalization costs.
van Agthoven et al. [34] The Netherlands; 6-center randomized
phase III trial; 1994-1998
Time horizon: start of first chemotherapy
course to 3 months after hospital
discharge
n 5 91 (auto: BM, PBSC)
Inpatient and outpatient; adult patients
Mean total cost of transplantation
phase:
Auto-BM: $19,000
Auto-PBSC: V15,008
Auto-PBSC HCTwas less costly than auto BM
HCT.
Hospital days were the main component of total HCT
costs.
The major costs during follow-up were blood
components and hospital stay.
van Agthoven et al. [35] The Netherlands; 4 centers; 1994-1999
Time horizon: from patient screening
up to 2 years after HCT
n5 97 (allo: MRD-BM, MRD-PBSC, MUD-BM, or PBSC)
Inpatient and outpatient; pediatric and adult patients
Average costs:
MRD BM: $98,334
MRD PBSC: V98,977
MUD: $151,754
The major cost components were hospitalization and
personnel.
For MUD HCT, nearly one-third of total costs were
related to donor search.
Allo indicates allogeneic; auto, autologous; MA, myeloablative; MRD, matched related donor; MUD, matched unrelated donor; URD, unrelated donor.
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Table 4. Summary of Cost-Effectiveness Analyses of HCT Published after 2000
Reference Data Source Population Characteristics ICER Conclusions
Lin et al. [6] United States; single institution; 2001-2006
Time horizon: initial hospitalization to 1-year
n 5 140 (costs for 76) (allo-MUD: PBSC, BM)
Pediatric patients
ICER for standard-risk subgroup: $687,108
(favoring BM)
ICER for high-risk subgroup: $1.69 million
(no clear benefit for either graft source)
For patients with standard-risk disease, BM was associated
with lower costs and greater effectiveness compared
with PBSC.
For patients with high-risk disease, no clear benefit was
seen for either donor source.
Kouroukis et al. [36] Canada; single institution; 1998-2000
Time horizon: initial therapy to not specified
n 5 52 (auto: melphalan and prednisone)
Adult patients
ICER for base case: $18,974
ICER for drug acquisition and clinic costs of
additional treatment with pamidronate:
$25,710 (favoring HCT)
Cost per life-year gained with HCT compares positively
with other interventions.
The highest HCT costs were related to hospitalization,
chemotherapy, intensive care unit admission, and use of
granulocyte-colony stimulating factor.
Yu et al. [11] Taiwan; single institution; 1994-2002
Time horizon: admission through ‘‘whole
treatment period’’ (cure or mortality)
n 5 106 (HiDAC-based therapy, allo, auto;
intensive therapy)
Adult patients
Mean cost per life-year saved:
HiDAC: $11,224
Allo: $21,564
HiDAC is more cost-effective than allo-HCT in patients
with acute myelogenous leukemia with either
intermediate or unknown cytogenetic risk.
Allo-HCTwas associated with higher costs than HiDAC or
auto-HCT.
Age, cytogenetic risk, and intensive therapy were
associated with higher overall survival
Costa et al. [30] International; multiple centers; articles
published between 2000 and 2005
Time horizon: transplantation, first-year, and
total 10-year cumulative costs
n 5 4,056 (allo: UCB, BM/PBSC)
Adult patients
ICER (compared with no HCT):
BM/PBSC: $16,346
UCB: $34,360
Most costs were incurred early in the course of HCT.
BM/PBSC sources should be the first option for unrelated
donors if clinically indicated, but UCB is a reasonable,
cost-effective substitute.
Imataki et al. [12] Japan; single institution; 2000-2002
Time horizon: admission until discharge,
up to 2 years after HCT
n 5 50 (allo-RIC, allo-MA)
Adult patients
ICER (MA compared with RIC): $469/year Hospitalization represented the largest proportion of
costs.
Total hospitalization was longer in MA compared with RIC.
MA and RIC were comparable in terms of cost and mean
survival.
Fagnoni et al. [29] Phase III multicenter GOELAMS 072 study;
1994-1999
Time horizon: costs followed from first
course of chemotherapy until last CHOP
course or PBSC hospitalization discharge
n 5 197 (conventional chemotherapy [CHOP];
auto-PBSC)
Pediatric and adult patients
ICER: V79,111 with auto-PBSC.
ICER for patients with high-intermediate
risk according to age-adjusted IPI:
V34,315 with auto-PBSC
Auto-PBSC might be considered cost-effective in patients
with NHL classified as high-to-intermediate risk
according to age-adjusted IPI.
Long-term effectiveness data were not included.
No indirect costs were included.
No quality-of-life information was included.
Allo indicates allogeneic HCT; auto, autologous HCT; HiDAC, High-dose arabinoside; IPI, International Prognostic Index; MA, myeloablative; MRD, matched related donor; MUD, matched unrelated donor; Non-
medical costs include patient time and productivity costs.
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Few studies reported to date have examined the
cost-effectiveness of HCT (Table 4). Findings in the
available studies are not consistent, given the variations
in comparison of treatmentmethods across studies. For
example, researchers have compared transplantation
andno transplantation [27],RICandconventionalmye-
loablative conditioning [12], and conventional chemo-
therapy and autologous chemotherapy with peripheral
blood stem cell (PBSC) support [29]. In a systematic re-
view and decision model analysis, Costa et al. [30] com-
pared unrelated bone marrow (BM) or PBSC HCT,
UCB HCT, and no transplantation in adult patients
with acute leukemia who were not expected to be cured
with chemotherapy. Compared with no transplanta-
tion, the estimated incremental cost-effectiveness ratio
(ICER) was $16,346 for BM/PBSC HCT and $34,360
for UCB HCT. The authors concluded that although
initial transplantation costs and treatment-relatedmor-
tality rates were high, there were long-term health ben-
efits compared with not undergoing transplantation.
The ICER rates were acceptable (\$50,000). These re-
sults suggest that if an unrelated donor is needed, BM/
PBSC should be the first option, but UCB is an accept-
able cost-effective alternative if a BM/PBSC donor is
not available. They also suggest that because UCB
transplantation is relatively new, future improvements
and progression on the learning curve might improve
its cost-effectiveness [30].
Comparing PBSC and BM HCT in pediatric
patients with acute myelogenous leukemia or acute
lymphoblastic leukemia, Lin et al. [6] found that the
cost-effectiveness of treatment differed based on the
patient’s disease status. For example, in standard-risk
disease, BM transplantation was associated with
greater effectiveness and lower costs compared with
PBSC transplantation. Further uncertainty analysis
suggested that BM transplantation was more cost-
effective in this group of patients. However, in the
high-risk group, BM transplantation was more expen-
sive andmore effective than PBSC transplantation. On
further uncertainty analysis, the authors were unable
to demonstrate a clear advantage of one donor source
over another.
Similar to the cost identification studies, drivers of
costs in cost-effectiveness studies included hospital
costs, disease risk, and complications.AREAS FOR FUTURE RESEARCH
Many economic aspects of autologous and alloge-
neic HCT need further evaluation. The costs of trans-
plantation need to be better described. The current
perspective costs relies on single-institution studies.
Multicenter studies or studies using databases that
capture costs from multiple institutions will providea better understanding of the costs ofHCT. Such stud-
ies can help identify and address specific questions re-
lated to these costs, for example, geographic variation
in costs and center practices and characteristics (eg, pe-
diatric versus adult centers) that may affect costs. Re-
search following this foundational work could focus
on investigating and identifying practices at specific
centers that are cost-effective and then translating
these practices to other centers to decrease the costs
of HCT without compromising patient outcomes.
As HCT outcomes improve and transplantation
center capacity increases, there is a greater need for
long-term follow-up of survivors and a better under-
standing of the costs associated with the long-term
care of HCT survivors. A long-term perspective is im-
portant for some newer transplantation modalities as
well. For example, UCB HCT may be associated
with higher up front costs secondary to the costs of
graft acquisition and graft failure, but the incidence
of chronic GVHD is lower in UCB HCT compared
with matched unrelated donor HCT, and thus the
overall costs of UCB HCT may be lower in the long
run. In addition, research examining the costs of up
front HCT versus treatment for relapsed disease is re-
quired (eg, multiple myeloma).
More research is needed to better understand the
costs of HCT to caregivers and patients. Including
patient-relatednonmedical and indirect costs (eg, tempo-
rary housing costs, transportation costs, lost productivity)
prospectively in studies may increase the understanding
of the true cost of HCT from patient and societal per-
spectives. This is particularly relevant as centers look at
outpatient HCT as a way to decrease the costs of
HCT. In this setting, there is the potential for the transfer
of some costs to patients and their caregivers (eg,
transportation, outpatient visit, prescription co-pays).
More cost-effectiveness studies that take into ac-
count transplantation risks and mortality are needed.
Cost-utility analyses that consider patients’ quality of
life will aid in evaluating the comparative effectiveness
of various transplantation modalities (eg, myeloabla-
tive versus RIC, UCB versus PBSCs/BM) and trans-
plantation versus no transplantation (eg, allogeneic
HCT versus chemotherapy only). Depending on the
economic question addressed in these studies, investi-
gators would ideally consider a long-term perspective
that takes into account risks and quality-of-life impair-
ments related to chronic GVHD. More emphasis also
should be placed in including economic endpoints in
future multicenter phase III studies related to HCT.ACKNOWLEDGMENTS
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